Teprotumumab
Based on 1 publication(s) in Google Scholar
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.46%
- CAS. Nr.: 1036734-93-6
- Molecular Weight:145.671 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Teprotumumab
More-
RT-PCR
Biologische Aktivität
Human IgG1 kappa
Human
IGF1R/CD221
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IGF-I R Protein, Human (HEK293, His, HY-P72606) can bind Teprotumumab. The EC50 for this effect is 1.568 ng/mL. -
Loaded Teprotumumab on AHC2 biosensor, can bind IGF-I R Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78142) with an affinity constant of 4.315E-10 M as determined in BLI assay.
Chemical Information
-
CAS. Nr. 1036734-93-6
-
Appearance Liquid
-
Molecular Weight 145.671 kDa
-
Color Colorless to light yellow
-
SMILES
[Teprotumumab]
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Clin Invest
Inhibition of aortic CX3CR1+ macrophages mitigates thoracic aortic aneurysm progression in Marfan syndrome in mice. [Abstract]2025 Jan 16;135(2):e178198. PMID: 39817456
Teprotumumab purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Jan 16;135(2):e178198. [Abstract]
Real-time PCR of gene expression in MFS patient-specific iPSC-derived VSMCs with conditioned media treatment in the presence of Teprotumumab (200 μg/mL; 24 h) or IgG. n = 4.
Reinheit & Dokumentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)